Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Climb 6.2% – Should You Buy?

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) shares were up 6.2% during mid-day trading on Friday. The stock traded as high as $9.36 and last traded at $9.31. Approximately 42,500 shares changed hands during mid-day trading, a decline of 69% from the average session volume of 138,779 shares. The stock had previously closed at $8.77.

Analysts Set New Price Targets

Separately, Jefferies Financial Group raised Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. Two equities research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Trading Up 1.3%

The company’s 50-day moving average is $9.06 and its 200-day moving average is $9.27. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.00 and a current ratio of 1.14. The firm has a market cap of $15.74 billion, a price-to-earnings ratio of 9.25, a P/E/G ratio of 3.14 and a beta of 0.08.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last posted its quarterly earnings data on Monday, August 3rd. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.18. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.13%. The firm had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $970.69 million. On average, research analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 earnings per share for the current year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Osaka. Founded in 1878, the company discovers, develops, manufactures and markets prescription medicines, with a focus on infectious diseases, central nervous system disorders and other areas of unmet medical need.

Shionogi’s portfolio includes Xofluza (baloxavir marboxil), an antiviral treatment for influenza, and F. (fostemsavir), an HIV treatment marketed in certain regions. The company also develops medicines for conditions including pain, psychiatric disorders and other diseases, while pursuing research in areas such as antimicrobial resistance and novel anti-infective therapies.

Shionogi primarily serves the Japanese market and has expanded its international presence through subsidiaries, licensing arrangements and commercial partnerships in North America, Europe and other regions.